elraglusib   Click here for help

GtoPdb Ligand ID: 11412

Synonyms: 9-ING-41 | compound 26 [PMID: 19338355]
Compound class: Synthetic organic
Comment: This entry was generated using the chemical structure that was submitted to the WHO for INN elraglusib. In that submission it is described as a glycogen synthase kinase inhibitor. The chemical structure also matches that of 9-ING-41 [2] which is a maleimide-based GSK-3 inhibitor [1] and an oncology clinical lead.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Click here for help
Canonical SMILES Fc1ccc2c(c1)c(co2)C1=C(C(=O)NC1=O)c1cn(c2c1cc1OCOc1c2)C
Isomeric SMILES Fc1ccc2c(c1)c(co2)C1=C(C(=O)NC1=O)c1cn(c2c1cc1OCOc1c2)C
InChI InChI=1S/C22H13FN2O5/c1-25-7-13(11-5-17-18(6-15(11)25)30-9-29-17)19-20(22(27)24-21(19)26)14-8-28-16-3-2-10(23)4-12(14)16/h2-8H,9H2,1H3,(H,24,26,27)
No information available.
Summary of Clinical Use Click here for help
Elraglusib (9-ING-41) has been advanced to clinical evaluation in solid and hematological malignancies (max Phase 2 as of Feb. 2021).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03678883 9-ING-41 in Patients With Advanced Cancers Phase 1/Phase 2 Interventional Actuate Therapeutics Inc.
NCT04218071 Actuate 1901: 9-ING-41 in Myelofibrosis Phase 2 Interventional Actuate Therapeutics Inc.
NCT04239092 9-ING-41 in Pediatric Patients With Refractory Malignancies. Phase 1 Interventional Actuate Therapeutics Inc.